Hodgkin lymphoma - AMC Hematologie

advertisement

Hodgkin lymphoma

Clinical presentation and treatment

Hodgkin lymphoma

• Malignant cell is a B lymphocyte

• Enlarged lymph nodes important clinical sign

• Thus: Confusion!

– Patients

– Students

• Q: what is difference with non-Hodgkin lymphomas where in most cases malignant cell is also of B cell origin?

Differences Hodgkin and non-Hodgkin lymphomas (NHL)

• Age distribution

– NHL : > 60 years peak incidence

– Hodgkin: bimodal

• Variabilty of clinical presentation

– Hodgkin: limited stage; rarely extranodal

– NHL: higher stage; frequently extranodal

• Treatment

– Radiotherapy very important part of treatment in

Hodgkin's disease

Hodgkin lymphoma

Clinical presentation

In general less complex than NHL!

• Lymphadenopathy

– Enlarged painless lymphnodes

– Supra-diaphragmatic in 90% (cervical, mediastinal)

• Hepato-splenomegaly: initially infrequent

• B symptoms in 25-30%

• Fever, often periodical; classically Pel-Ebstein

• Night sweats

• Weight loss (> 10% within 6 months)

Hodgkin lymphoma

Clinical Staging

• History/ Physical examination

• CT scan neck, thorax, abdomen

• 18 FDG-PET scan

• Bone marrow biopsy

Hodgkin lymphoma

Ann Arbor staging

Hodgkin lymphoma

Standard therapy in 2012

• Stage I/II

– Favorable

– Unfavorable

(2-)3 x ABVD + 30 Gy IN-RT

4 x ABVD + 30 Gy IN-RT

• Stage III/IV 8 x ABVD

Role of radiotherapy in stage III/IV

Hodgkin lymphoma

• CR after adequate chemotherapy no radiotherapy

• PR after adequate chemotherapy radiotherapy

Treatment Results ?

Survival after Hodgkin lymphoma

Radiotherapy and/or chemotherapy radiotherapy

No therapy

From H.S. Kaplan, 1981

Long term survival of Hodgkin lymphoma

EORTC/GELA

Favier et al, Cancer 2009;115:1680-1691

Treatment results in Hodgkin lymphoma at 5 years

Stage Prognosis RFS

I/II Favorable 92 % unfavorable 89 %

III/IV 75 %

OS

98 %

94 %

86 %

Treatment of Hodgkin lymphoma summary Stage I/II

• Excellent results

• Future

– maintain results

– reduce (late) toxicity

- reduce/ omit Radiotherapy?

- reduce Chemotherapy

– PET guided treatment (interim; post Tx)?

“Early” interim FDG-PET predicts prognosis

M Hutchings et al, Blood 2006;107:52-9

Treatment of Hodgkin lymphoma summary Stage III/IV

• Results moderate/good (cf DLBCL!)

• Future

– Improve results without increasing (late) toxicity

- more intensive chemotherapy?

– PET guided treatment

• Interim: escalate if positive?

• Post Tx: if positive radiotherapy/ HDT+ AuSCT?

Treatment for relapsed

Hodgkin lymphoma

• 15-30% of all HL patients will relapse and require secondline treatment

• High-dose chemotherapy and autologous stem cell transplantation:

- superior over conventional chemotherapy

(Linch et al., Lancet 1993, Schmitz et al., Lancet 2002)

- remains the standard of care for relapsed HL

(except very late relapse?)

High Dose CT + AutoSCT in relapsed HL

Relapse

Primary resistant

PFS @ 5 yrs

%

45-60

OS @ 5yrs

%

50-65

20-30 20-30

The reverse of the success

Successfull treatment of HL

Long term survival

Late effects of treatment

m Hodgkin: Late Toxicity of Treatment

• Excess mortality

– secondary malignancies

– cardiac disease

• Excess morbidity / decreased Q.O.L

– cardiac disease

– pulmonary disease

– infertility

– fatigue

m.Hodgkin : Late Toxicity of Treatment

Secondary Malignancies

Relative

Risk

AML

NHL

70.8

18.6

Solid 2.4 tumors

-- lung 4.2

-- breast 2.5 all 3.5

Absolute

Excess Risk per 10,000 pat. per yr

15.5

10.7

29.3

13.5

11.3

56.2

Absolute

Excess Risk in 10-yr survivors

9.0

27.8

74.4

33.8

39.5

111.7

m.Hodgkin : Late Toxicity of Treatment

Cardiac disease

• coronary insufficiency myocardial infarction

• acute cardiac arrest

• pericarditis

• cardiomyopathy

• valvular abnormalities

RR 1.9 - 3.7

RR 1.9 - 3.1

RR 1.4 - 5.1

m.Hodgkin : Late Toxicity of Treatment

Risk Factors for Cardiac Disease

• Mediastinal RT dose > 30 Gy

• Orthovolt RT (before 1967)

• Adriamycine containing CT

• Age at RT < 20 yr

• Hypertension

Veranderingen bestralingsgebied

H9

CT+RT klierregio

Klassiek mantelveld

Dank aan: R vd Maazen

H10

CT+RT klier

Treatment of Hodgkin lymphoma

• Progress can only be made by including patients in clinical studies!!

Download